This present study evaluates the potential of adenovirus-mediated gene transfer (AMGT) to the prostate of normal laboratory beagles. Many morphological and histological similarities can be noted between dog and human prostate. Moreover, dogs can spontaneously develop prostate cancer with a clinical and biological outcome identical to that in man. Firstly we showed the capacity of human adenovirus to infect canine prostatic cells in vitro. Secondly, we injected transrectally in the dogs' prostates 2610 9 plaque forming units of a ®rst generation recombinant adenovirus vector harboring the reporter gene b-galactosidase (AdRSVbgal). Seven days after the adenoviral delivery, we observed expression of the transgene in both prostates, and exclusively in epithelial cells. Despite a cellular and a humoral immune response, the infusion appeared safe, since the dogs had no fever and presented no urinary symptoms. This study constitutes the ®rst evaluation of AMGT in dog prostate and provides a basis for gene therapy treatment of prostate carcinoma-bearing patients.
Introduction
Prostate cancer is on the verge of becoming the most common malignancy in the male population of Western countries. No etiological factors have been precisely identi®ed. However, men over 55 years old are in the high risk category. 1 Besides surgery and radiotherapy, androgen ablation is still the only treatment available. It allows temporary cancer regression until the tumor ultimately changes to an androgen-independent state. At that stage, no current treatment, including cytotoxic chemotherapy, is effective in increasing survival.
Gene therapy is proposed as a new therapeutical approach. Among the vectors available for gene transfer, adenovirus is particularly attractive. The most highly touted advantage of adenovirus-mediated gene transfer (AMGT) is that adenoviruses (Ad2 and Ad5) that are engineered into the currently used recombinant vectors (rAds) do not cause tumors in rodents and appear to be responsible for only mild respiratory problems in humans. 2 In addition, recombinant Ad vectors are stable and high virus titers are readily obtainable, which allow direct in vivo gene transfer. The Ad genome rarely integrates into the host genome (for review, see Reference 3) and therefore has little chance of activating a dormant gene or interrupting a tumor suppressor gene. Finally, AMGT for prostatic adenocarcinoma, which is a slowgrowing tumor, is conceivable since adenoviruses (Ads) are known to infect actively as well as non-actively dividing cells ef®ciently.
Several animal models have been used to study different therapeutical approaches for prostate cancer. 4 ± 10 The Dunning rat R3327-MatLyLu prostatic tumor model is an androgen-independent, fast-growing tumor which spreads to lung and lymph node. It does not appear to induce tumor-speci®c CTL and thus does not demonstrate any signs of intrinsic immunogenicity. Hence it is the most extensively used model for cancer gene therapy studies which require an intact immune response. 4 ± 6 Another model, the RM-1 mouse prostate cancer cell line subcutaneously injected in a syngeneic C57BL/6 adult male, has been used to evaluate the potential role of cytotoxic AMGT. 8 However, all these studies share a common pitfall: they target rapidly dividing cells, whereas human prostate cancer tends to be a slow-growing tumor.
By contrast, dogs, as well as the Lobund ± Wistar rat, can spontaneously develop slow-growing prostatic cancer resembling the human disease. In addition, prostate cancer in these models is subject to local controls very different from those present in the ectopic sites normally used in the mouse or the Dunning rat models described above. Indeed, vascular supply, hormonal in¯uence and immunological components have been proven to play a much greater role. 4 Spontaneous canine prostate cancer offers additional advantages to the Lobund ± Wistar rat model. Firstly, the local and metastatic clinical outcome of canine prostatic cancer is identical to that in man. 11 Secondly, loco-regional structures are easily dissectable and iliac lymph nodes can be sampled and ®nally, the anatomy of the urinary system in dogs is very close to men's. It is for these particular reasons that the dog appeared to us to be the appropriate animal for preclinical studies of AMGT for prostate cancer.
In the present study, a ®rst generation (E1 and E3 deleted) adenoviral vector harboring the reporter gene b-galactosidase (AdRSVbgal) was used to ®rst assess the capacity of a human adenovirus to infect canine prostatic cells in vitro, and then to investigate in vivo the feasibility and the ef®ciency of a direct intraprostatic delivery by transrectal injection in dogs. This route of administration mimics a clinical viral infusion. We showed that this particular form of gene transfer is ef®cient and that epithelial cells are selectively transduced by a human adenoviral vector: seven days post-injection, transgene expression was observed in the prostate of the two animals studied, and b-galactosidase positive prostatic cells were exclusively epithelial cells. The AMGT generated no local or general toxicity. However, an in¯amma-tory reaction, strictly limited to the prostate, and an antiadenoviral immune response were observed.
Materials and methods

Cell cultures and recombinant adenoviral vector
The canine prostatic cell line DPC-1 was derived from a spontaneous canine (Boxer) prostatic adenocarcinoma. It was isolated from epithelial primary cultures obtained after mechanical dissociation of the prostate tumor. The DPC-1 cells were grown in RPMI-1640 medium (Gibco BRL) supplemented with 5% fetal calf serum (FCS) and 2 mM glutamine. In this medium, they have been maintained for 12 months and 100 passages.
The canine kidney cell line DK 12 was grown in Dubbelco's modi®ed Eagle's medium (Gibco BRL) supplemented with 10% FCS.
The AdRSVbgal construction has been described previously. 13 Viral stocks were prepared on 293 cells, as previously described, 14, 15 and puri®ed twice on isopicnic CsCl gradiant. Desalting was performed using Pharmacia columns (Orsay, France). Viruses were divided into aliquots and kept in phosphate-buffered saline (PBS)-10% glycerol at 780 C. Titers were calculated by plaque analysis on 293 cells.
Infection of cultured cells by AdRSVbgal
DK and DPC-1 cells were plated in six-well dishes and infected as con¯uent monolayer 24 h later at a density of 1.1610 6 cells/well and 1610 6 cells/well, respectively. The two cell lines were infected with AdRSVbgal for 4 h at 37 C in a minimal volume of medium (500 ml) at a multiplicity of infection (MOI) of 0, 10, 100, 250, 500 or 1000 plaqueforming units (pfu)/cell. Each experiment was performed in duplicate. Cells were tested for b-galactosidase activity 48 h post-infection using histochemical methods. 13, 16 The ef®ciency of AdRSVbgal infection was determined by counting X-gal expressing cells in seven high-power ®elds (4006magni®cation) per well. The number of blue cells per well (N) was estimated as follows:
N numer of lue ells ounted in seven fields Â 1225 7
with 1225 total number of high-power ®elds in a well of a six-well plate. The percentage of X-gal expressing cells was calculated with the formula:
7
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Inoculation of dogs
Two year old beagles obtained from the Ecole Nationale Ve Âte Ârinaire de Maisons Alfort (ENVA) were used in this study. Pre-and post-operative examinations were performed, including ultrasound imaging of the urogenital system before and seven days after the adenoviral injection, clinical assessment and temperature measurement. Moreover, blood and urine samples were regularly collected throughout the study. Surgery was carried out under general anesthesia with 10 mg/kg of Nesdonal (Rho Ã ne-Merieux) in addition to gas relay under Halotane used at a concentration ranging from 1 ± 2% (Belamont).
Under digital guidance, 2610 9 pfu of AdRSVbgal diluted in 500 ml of PBS buffer was administered directly into the prostate by a single transrectal injection with a needle of 0.9 mm in diameter.
Organ sampling, histopathology and X-gal staining At day seven, the animals were sacri®ced with 15 ml of sodium pentobarbital (Dolethal). The prostate from each dog was surgically removed and opened along a vertical axis, allowing a visualization of the urethral mucosa. After careful dissection, prostate samples were either (1) embedded in O.C.T. (TissueTek) and snap-frozen in liquid nitrogen for frozen sections; (2) ®xed in AFA (acetic acid 5%, absolute ethyl alcohol 75%, 2% of formalin (40%), water 18%) for paraf®n block preparations; or (3) directly frozen at 780 C for PCR analysis. It is worth noting that the entire prostates were sampled and that each frozen or paraf®n prostate sample represented a horizontal slice of an entire prostatic lobe. Similar procedures were performed on both loco-regional organs (urethra, spermatic ducts, epididymis, testis, bladder, rectum, bladder-rectum septum and iliac lymph node) and distant organs (liver, lung, spleen and kidney).
b-galactosidase activity was revealed on semi-serial cryosections (10 mm thick) by incubation in 4 mM K 3 Fe (CN) 6 C. Frozen sections were counterstained in hematoxilin-eosin.
Paraf®n sections (5 mm thick) were stained in hematoxilin-eosin-saffron.
Immunohistochemistry
Immunohistochemistry performed on acetone-®xed frozen sections was used to detect cells positive for CD4, CD8, CD21, CD11b or CD11c canine surface markers. Frozen sections were incubated with undiluted rat anti-canine CD4 IgG2a monoclonal antibody (Serotec), and subsequently with a mouse anti-rat IgG2a biotinconjugated monoclonal antibody (Pharmingen) at a dilution of 1/100. For the detection of canine CD8
, sections were incubated with a rat anti-canine CD8 monoclonal antibody (Serotec) at a dilution of 1/100, and then with a mouse anti-rat kappa light chain biotin-conjugated monoclonal antibody at a dilution of 1/20 (Biosys). Streptavidine peroxidase (1/20) (Vector) and 3-amino-9-ethylcarbazole (AEC, Sigma) were used for revealing the markers.
Detection of canine CD21, CD11b, and CD11c expressing cells was also performed on acetone-®xed frozen sections. The primary mouse monoclonal antibodies (generous gift of PF Moore) were used at a dilution of 1/25, followed by a goat biotinylated anti-mouse polyclonal antibody (Pharmingen) used at a dilution of 1/500. Positive cells were visualised with streptavidin peroxidase (1/20) (Vector) and AEC. As a negative control, the primary antibody was omitted in each immunostaining.
Double staining for CD1c and CD11c surface markers on acetone ®xed sections of frozen prostate was carried out as follows: sections were ®rst incubated with anticanine CD11c primary mouse monoclonal antibodies at a dilution of 1/25, followed by a rabbit anti-mouse Ig coupled with alkaline phosphatase at a dilution of 1/ 100 (DAKO). Positive cells were visualised using mouse APAAP (1/25) (DAKO) and fast blue (Vector Blue, Vector) supplemented with 0.2 mM levamisole (Levamisole, DAKO). After washing in PBS supplemented with 7.5% BSA, sections were incubated with a mouse biotinylated anti-canine CD1c monoclonal antibody at a dilution of 1/ 200. Revelation included streptavidine peroxidase (1/20) (Vector) and AEC.
DNA Extraction from¯uids and organ samples for PCR analysis
All clinical samples were treated with virus lysis buffer 17 prior to phenol-chloroform extraction and ethanol precipitation. Organ samples were resuspended in 500 ml of virus lysis buffer supplemented with proteinase K at a ®nal concentration of 0.2 mg/ml, and incubated overnight at 56 C. After a further incubation of 10 min at 100 C, the lysates were centrifuged for 5 min at 5000 rpm. Supernatants were used for DNA extraction with an equal volume of phenol:chloroform:isoamyl-alcohol (25:24:1), precipitated, washed with cold 75% ethanol, and resuspended in 50 ml of TE buffer (10 mM Tris pH 8.0, 1 mM EDTA). RNA was eliminated using ®ve units of RNAse A (Boehringer).
Urine samples (400 ml) were ultra ®ltered with ultra free MC ®lter units (Millipore) to eliminate the inhibitory effect of urea on PCR, as previously described. 18 Retention products were rinsed twice with 400 ml of bidistilled water, collected with 400 ml of virus lysis buffer and incubated for 1 h at 56 C. The procedure described above for organ sample DNA extraction was then used.
Sera samples (100 ml) were supplemented with 100 ml of TE buffer and directly resuspended in 500 ml of virus lysis buffer, followed by the same DNA extraction procedure as described above.
Virus DNA used for control experiments was prepared as described above, from infected 293 cells. One positive extraction control from 10 6 293 cells containing 10 ± 50 pfu of AdRSVbgal, and negative extraction controls made of 200 ml of TE buffer were included in each batch.
LacZ adenovirus PCR
Two pairs of primers were used in a nested PCR to detect the presence of the reporter gene from AdRSVbgal. The outer primers were OTG5347 (AdRSVbgal nucleotides 4235-4258) and OTG 4908 (AdRSVbgal nucleotides 4809-4832). The inner PCR primers were OTG1 (AdRSVbgal nucleotides 4270-4291) and OTG5349 (AdRSVbgal nucleotides 4618-4641). These primer pairs generated fragments of 598 bp and 371 bp, respectively. All PCR procedures were performed as previously described. 19 PCR speci®city was assessed using target DNA obtained from various cell lines (293, Hep2 (derived from a human epithelial carcinoma and permissive for wild type adenovirus), human ®broblast), and several serotypes of adenoviruses (Ad1, Ad2, Ad3, Ad5, Ad6, Ad7, Ad9, Ad10, Ad11, Ad16, Ad22, Ad30, and Ad40). Ampli®cation fragments were observed only using template DNA from AdRSVbgal recombinant adenovirus.
At least one negative PCR control (5 ml TE buffer) and three positive PCR controls containing 10 fg, 1 fg and 0.1 fg of recombinant adenovirus DNA were included in each PCR assay for determination of sensitivity. Sensitivity of the PCR was 0.1 ± 1 fg viral DNA per reaction corresponding to 2.5 ± 25 adenovirus genomes. For most samples, both 5 ml of undiluted and 5 ml of diluted (1:10) DNA extract were assessed. An internal PCR control containing 2 fg of AdRSVbgal DNA accompanied each assessment. Therefore, false negative results due to technical problems, such as poor quality of the genomic DNA or presence of PCR inhibitors, were detected.
Anti-adenoviral antibody assays
Ad5 speci®c IgM antibody in dog sera was determined by ELISA. A 96-well plate was coated with 100 ng of heatinactivated Ad d1324 20 per well and incubated overnight at 4 C. Wells were saturated with 5% milk diluted in Trisbuffered saline (TBS) supplemented with Tween 20 at a ®nal concentration of 0.05% (TBST) for 2 h at room temperature, washed with TBST and then incubated with 100 ml of the serial diluted sera samples (1:50 ± 1:6400) for 1 h at room temperature. After washing, wells were incubated (1 h, room temperature) with the diluted (1:5000) goat anti-canine IgM antibody (Cappel). Bound antibody was detected with horse radish peroxidase-conjugated donkey anti-goat IgG polyclonal antibody (Santa Cruz Biotechnology) (1 h, room temperature) followed by incubation with the soluble peroxidase substrate (OPD tablets, SIGMA) and spectrophotometric reading.
Serum-neutralizing antibodies speci®c for human adenovirus were evaluated as previously described. 21 Sera were incubated at 56 C for 30 min to inactivate complement. Serial dilutions of dog sera (1:40 ± 1:1280) in MEM supplemented with 10% FCS were incubated with 5610 5 pfu of AdRSVbgal for 1 h at 37 C. Each mixture was then used to infect 293 cells plated in a 96-well dish (5610 4 cells/well). After a 1 h incubation, 100 ml/well of MEM supplemented with 10% FCS was added. Twenty hours after infection, cells were tested for b-galactosidase activity using histochemical 16 and¯uorometrical methods. Brie¯y, cells were washed and incubated 1 h at 37 C with 100 ml of lysis buffer (6 mM Na 2 HPO 4 , 10 mM KCl, 0.1 mM MgSO 4 , 50 mM b-Mercaptoethanol and 0.5% Triton Â100) supplemented with 1 mg/ml of b-galactosidase substrate (4-methyl-umbelliferyl b-D-galactoside) (Sigma). Resultant¯uorescence was measured in a Cytouor 2300 Fluorescence Plate Reading (Millipore). For each serum dilution, the inhibition percentage of transduction (%IT) was calculated as follows: Thirdly, these cells showed a high tumorogenicity when subcutaneously injected into male athymic mice. Tumor formation was induced in all animals (n 10) within 2 ± 4 weeks. However, anchorage-independent growth tested in soft agar did not lead to colony formation (manuscript in preparation).
Evaluation of the ef®ciency of in vitro AMGT to a prostatic canine cell line; comparison with the DK cell line
In order to evaluate the ef®ciency of infection of canine prostatic cells by a recombinant human adenoviral vector, DPC-1 cells were infected in vitro with AdRSVbgal at a MOI of 0, 10, 100, 250, 500 or 1000 pfu/cell. The DK kidney cell line was used as a control. The infected cells were stained for b-galactosidase expression 48 h post-infection. At 48 h, both cell lines reached their highest transfer percentages at the 10 ± 100 MOI range, which are 13% and 22% for DPC-1 and DK cell lines, respectively ( Figure 1 ). It is also worth noting that there were decreasing numbers of b-galactosidase positive cells with higher MOI. This phenomenon, which is most likely due to a cytopathic effect, was most pronounced for the DK cell line.
Clinical ®ndings and macroscopic examination after direct intraprostatic delivery of AdRSVbgal to dogs
During the post injection period of 2610 9 pfu of AdRSVb gal, the dogs had no fever and were free of weight loss and anorexia. No urinary symptoms, such as bladder Figure 1 In vitro infections of the DPC-1 prostatic canine cell line. DPC-1 cells were infected in vitro with AdRSVbgal at MOI of 0, 10, 100, 250, 500 or 1000 pfu/cell and stained for b-galactosidase activity 48 h post infection. As a control, the same procedure was performed on the DK kidney canine cell line.
Gene
At day seven, a gross examination was performed. The prostate of both dogs exhibited a slight enlargement. This ®nding was con®rmed by comparative analysis with the pre-and post-injection ultrasound examinations (data not shown). Upon opening of the gland, the mucosa of the urethra and the verumontanum were normal, as well as most of the prostatic tissue, except for a hemorrhagic area observed in both dogs, suggestive of a needle print. The adjacent organs such as bladder, rectum, spermatic ducts, urethra, epididymis, testis and iliac lymph nodes appeared normal. No in¯ammatory lesions of the subperitoneal area were observed. Distant organs, such as liver, lung, spleen and kidney were normal.
Histology and ef®ciency of gene transfer
Paraf®n sections exhibited in¯ammatory and epithelial changes (Figure 2, panel A and B) , strictly limited to a de®ned area separated from the normal gland by sharp borders. The in¯ammatory in®ltrate consisted mainly of lymphocytes and plasmocytes ( Figure 2, panel B) .
The feasibility and ef®ciency of a direct delivery of the recombinant adenovirus AdRSVbgal were evaluated using histoenzymological staining for b-galactosidase activity on frozen prostate sections. In both animals, the transgene was exclusively expressed in the glandular epithelium ( Figure 2 It is noteworthy that analysis of the whole gland showed that the marked mononuclear in®ltrate described above not only surrounded b-gal expressing cells, but also extended far beyond the transduced cells (data not shown).
Loco-regional structures such as testis, epididymis, spermatic ducts, bladder and rectum were negative for b-galactosidase activity, except for a very restricted patch in a small nerve of the bladder neck in dog number 2 (data not shown). The cortical area of an iliac lymph node of this dog also contained several patches of b-galactosidase positive lymphoid cells (Figure 2, panel G and H) .
Histoenzymological staining for b-galactosidase activity performed on distant organs, such as liver, lung, spleen and kidney was negative. Neither in¯ammatory nor cytopathic effects were observed in distant organs (data not shown).
Vector dissemination
To further evaluate the extent of AdRSVbgal dissemination, we carried out PCR analysis of a wide range of tissue samples collected at day seven, and on urine and serum samples collected from the two dogs at days one, two, ®ve and seven post-injection. Figure 3 summarizes the observed PCR patterns and illustrates the results presented in Table 1 .
In some cases, AdRSVbgal sequences could not be detected in undiluted DNA samples, probably because of a poor quality of genomic DNA or due to the presence of inherent PCR inhibitors. The pattern illustrating this particular situation is shown in Figure 3 , lane 5. The bladder neck, the bladder rectum and the liver of dog number 1 were all found negative for AdRSVbgal sequences, whereas in dog number 2, these sequences were detected both in the bladder rectum and the liver (Table 1) .
Using PCR analysis, AdRSVbgal sequences were no longer detectable in non-diluted urine at day ®ve and day seven for dog number 1 and dog number 2, respectively. PCR analysis performed on a 1:10 dilution of urine DNA extracts suggested that the quantity of AdRSVbgal genomes that disseminated in dog number 2's urine was more signi®cant than that in urine of dog number 1. Using PCR analysis with undiluted serum DNA, the transgene was only weakly detectable at day one for dog number 1 but still detectable at day ®ve for dog number 2 ( Table 1) .
Analysis of in¯ammatory cell populations by immunohistochemistry
To more precisely determine which lymphoid subtypes were involved in the in®ltrate observed in both prostates, we performed immunostaining directed against several surface markers speci®c for canine CD4, CD8, or B lymphocytes (CD21). In addition, we used a panel of antibodies directed against CD11b (usually expressed on macrophages) and CD11c (usually expressed on dendritic antigen presenting cells (APC)). The negative controls consisted of the omission of primary antibodies on each section. The complete procedure was also performed on normal prostatic samples obtained from a non-injected dog (data not shown).
CD4 and CD8 expression cells were detected between the glandular acini, whereas the acini themselves remained completely negative. CD4 and CD8 positive cells were also detected at the periphery of the glandular lobules and in the ®bromuscular tissue (Figure 4 , panel A and B). Numerous CD21 B lymphocytes were observed in patchy areas within the stroma (Figure 4 , panel C).
CD11b and CD11c expressing cells were signi®cantly more numerous than CD4 and CD8 populations. Moreover, con¯uent patches of large macrophage-like cells were detected. These cells were present both in the stroma surrounding the glands and in the glandular lumen (Figure 4, panel D and E) .
In some cases, macrophages can upregulate surface markers, such as CD11c, which are usually expressed on dendritic APC. In order to con®rm the immunophenotype of the CD11c positive cells, we double-stained frozen prostate sections for CD11c /CD1c
. Macrophages (CD11c /CD1c
7
, blue stained cells) were predominant (Figure 4, panel F) . The exact nature of the cells present within the glandular lumen was dif®cult to assess. Indeed, we could not exclude the possibility of non-speci®c staining of pre-necrotic macrophage-like 
Assessment of humoral response; titration of neutralizing adenovirus-speci®c antibodies in dog sera
To determine whether a systemic humoral response to adenoviral proteins developed after the intraprostatic injection of AdRSVbgal, we searched by ELISA for the presence of Ad5-speci®c IgM antibodies in both dogs' sera collected at days one and seven after the adenoviral delivery. Sera collected at day one were used as controls, since IgG and/or IgM production cannot occur so early after a viral infection. As shown in Figure 5 , an increase in IgM antibodies in dog number 2 serum was observed at day seven, whereas for dog number 1, no elevation in IgM antibodies occurred. Finally, we assessed the presence of neutralizing antibodies to Ad5 antigens in the dog sera collected at days one and seven post-injection. We did so by measuring the capacity of serial dilutions of serum samples to inhibit the infection of 293 cells with AdRSVbgal. At day one, the inhibition percentage of the transduction was insigni®cant for both dogs. However, at day seven, the inhibition reached a percentage of 15 for dog number 1 and of 50 for dog Figure 3) number 2, for the 1:40 dilution. As could have been expected, inhibition at day seven decreased gradually with increasing serial dilution; in dog number 2, 10% inhibition was still detectable at the 1:320 dilution ( Figure 6 ).
Discussion
Previous in vitro AMGT studies have shown successful transfer and expression in rodent models of prostate cancer. 7 ± 9 However, these experiments targeted rapidly dividing cells, whereas human prostate cancer tends to be a slow-growing tumor. Our investigations in an animal which can spontaneously develop prostate carcinoma with a growth rate and a clinical (local and metastatic) outcome similar to human's appeared essential for the evaluation of a preclinical study of AMGT for prostate cancer, and should be of value for coming clinical trials.
Our data demonstrates the capacity of a human adenovirus to infect canine prostatic cells in vitro (Figure 1) . 
/CD1c
7 and thus macrophages, are present outside the glands, whereas CD11c /CD1c purple cells, which are likely to be dendritic cells rather than macrophages (based mainly on CD1c expression), were rare in this location (bottom right corner, 630Â).
In addition, we show the feasibility and the ef®ciency of gene transfer after an intraprostatic delivery by transrectal injection of dogs with a recombinant adenovirus harboring a reporter b-galactosidase gene. The transgene was found to be exclusively expressed in the glandular epithelium of both prostates (Figure 2 ). These observations con®rm our in vitro data generated by infection of primary cultures of human epithelial and ®broblastic cells, as well as of human epithelial prostatic cell lines PNT1A and PNT2 24 with AdRSVbgal, and our in vivo experiments on human prostatic adenocarcinoma grafted in nude mice (data not shown). Knowing that more than 95% of human prostate cancer are derived from glandular epithelium, 25 this selective transduction of epithelial cells by a recombinant adenovirus makes this viral vector an attractive candidate for treatment of prostatic adenocarcinoma by gene transfer.
The second step of our work was to analyze the possible side effects associated with an intraprostatic delivery by transrectal injection of a recombinant adenovirus vector. No signs of local or general toxicity were observed. The dogs had no fever, were free of weight loss or anorexia, and did not show any urinary symptoms, suggesting that the route of administration and the dose of AdRSVbgal delivered are safe.
Although local or general toxicity symptoms were absent, a strong in®ltrate was observed in the prostate at day seven. We demonstrated that both speci®c (CD4, CD8, B lymphocytes (CD21 )) and non-speci®c (that is, macrophages and dendritic cells) immune subpopulations were implicated in the cellular response ( Figure 4) . Furthermore, an adenovirus-speci®c humoral immune response was induced following the intraprostatic delivery of AdRSVbgal. Indeed, an increase in IgM directed against Ad5 adenoviral proteins developed in dog number 2 ( Figure 5 ). In addition, a slight increase in IgG antibodies was observed at day seven in dog number 2, compared to day one. Quite surprisingly, the level of Ad5-speci®c IgG antibodies was extremely high in both dogs at day one. Two hypotheses may explain these data. Firstly, the dogs may have previously been in contact with human adenovirus. In this case, the important humoral immune response could only have been induced by exposure of the dogs to large quantities of human adenovirus. This seems very unlikely. The second possibility is that CAV-2 speci®c IgG antibodies, induced by CAV-2 vaccination which is performed on all dogs in France, recognize antigenic epitopes carried by both human and canine adenoviruses. This second hypothesis is the most likely, since the preexisting antibodies were not able to neutralize human adenovirus. Indeed, the inhibition percentage of transduction at day one was insigni®cant in both dogs. However, seven days after the adenoviral delivery, neutralizing antibodies developed in both dogs ( Figure 6 ).
The immune response elicited by ®rst-generation adenoviral vectors (E1 and E3 deleted) is a signi®cant limitation for AMGT. 26 ± 28 Nevertheless, the recruitment of activated immune cells induced by an adenoviral delivery may be an advantage for a cancer gene therapy approach. Viruses, such as the Newcastle Disease Virus (NDV), have been used to modify tumor cells' surface and thereby to activate and predict immune responses against tumor cells.
29 ± 31 However, in¯ammatory cells are also directly responsible for the transient expression of the transgene; in addition, the setting of an adenovirus-speci®c humoral immune response makes adenoviral readministrations dif®cult. Two major factors that are potentially responsible for the transient transgene expression and the in¯am-mation mediated by AMGT are the transgene itself 21, 32, 33 and the viral antigens. 28,34 ± 38 To optimize the persistence Figure 5 Detection by ELISA of adenovirus-speci®c IgM in the serum one and seven days after the intraprostatic delivery of AdRSVbgal. An increase in IgM in dog number 2 is observed at day seven. of adenoviral vectors in vivo, E1 and E4 defective adenoviruses have been constructed and assayed in LacZ transgenic mice. These studies suggest that the additional inactivation of E4 is a prerequisite for stable gene delivery in mouse liver. 39, 40 The use of new generation vectors, less immunogenic, would be helpful for AMGT of prostate cancer.
The PCR analysis, demonstrated that adenovirus did not persist in urine beyond day two in dogs number 1, and day ®ve in dog number 2. This difference between the dogs could be explained by a higher viral spread in the bladder of dog number 2. The observed pattern of AdRSVbgal dissemination in distant and loco-regional organs was quite different in both animals as well. AdRSVbgal sequences were observed in the liver of dog number 2, but these did not induce any liver damage, since the transaminase levels were perfectly normal seven days after the adenoviral delivery (data not shown). Since the liver is known to be the major organ infected after an intravenous adenoviral administration, 41 the observed PCR signal in the liver of dog number 2 strongly suggests that during the adenoviral delivery, viral particles spread into the general circulation. This hypothesis is supported by the positive correlation between the extent of the viral dissemination and the strength of the humoral in¯amma-tory reaction; both vector dissemination and humoral immune response were more pronounced in dog number 2 (Table 1 , Figures 5 and 6 ). As far as the bgalactosidase positive cells observed in the cortical area of an iliac lymph node of dog number 2 are concerned, it is possible that the adenoviral vector diffused from the prostate to the iliac lymph node, which is the ®rst site of invasion by metastasis in prostate cancer. 42 
Conclusions
In summary, this study shows the feasibility of a direct intraprostatic deliver of adenovirus to dogs. The observed preferential transduction of epithelial cells and the possible spread of the virus into iliac lymph nodes makes this gene delivery approach interesting for the treatment of local and invasive prostate cancer. For the latter case, the use of tissue-speci®c promoters should limit transgene expression to prostate-derived cells. The viral infusion appears safe, despite a strong in¯ammatory reaction observed in both prostates and despite the development in one of the dogs of an adenoviral-speci®c humoral immune response, due most likely to viral dissemination. These side effects can be circumvented by the optimization of gene transfer techniques and the use of new generation vectors. This study involving AMGT to dog prostate provides an essential basis for gene therapy treatment of prostate carcinoma-bearing patients.
